東北大学病院は、宮城県仙台市青葉区星陵町に所在する総合病院であり、国立大学法人・東北大学に付属する大学病院である。 日本の大学病院の中では最も長い190年を超える歴史を持つ。 厚生労働省より、国際水準の臨床研究等の中心的役割を担う国内の中核病院として、「臨床研究中核病院」に指定されている。

During the past decade, Tohoku University Hospital conducted 158 clinical trials. In the 10-year time frame, 158 clinical trials started and 67 clinical trials were completed, i.e. on average, 42.4% percent of trials that started reached the finish line to date. In the past 5 years, 93 clinical trials started and 49 clinical trials were completed. i.e. 52.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tohoku University Hospital" #1 sponsor was "Pfizer" with 24 trials, followed by "Boehringer Ingelheim" with 14 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored, "Celgene" with 10 trials sponsored and "Incyte Corporation" with 10 trials sponsored. Other sponsors include 123 different institutions and companies that sponsored additional 72 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tohoku University Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 9 trials as a collaborator, "Eli Lilly and Company" with 6 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Tohoku University Hospital" are "Multiple Myeloma" (9 trials), "Systemic Lupus Erythematosus" (7 trials), "Ovarian Cancer" (6 trials), "ALS" (5 trials) and "Breast Cancer" (4 trials). Many other conditions were trialed in "Tohoku University Hospital" in a lesser frequency.

Most popular intervention types in "Tohoku University Hospital" are "Drug" (179 trials), "Biological" (13 trials), "Other" (13 trials), "Device" (9 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (52 trials), "Rituximab" (11 trials), "Dexamethasone" (7 trials), "Carboplatin" (6 trials) and "Daratumumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Tohoku University Hospital" are 185 trials for "All" genders, 11 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Tohoku University Hospital". undefined are not yet recruiting, 49 are recruiting, 42 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 85 completed trials in Tohoku University Hospital, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Tohoku University Hospital, 20 "Phase 1" clinical trials were conducted, 65 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 4 trials that are defined as “Not Applicable".